Dec-14-20 Initiated
Jefferies
Buy
$200
Aug-06-20 Reiterated
H.C. Wainwright
Buy
$132 → $290
Aug-05-20 Upgrade
JP Morgan
Neutral → Overweight
$275
Aug-05-20 Downgrade
Ladenburg Thalmann
Neutral → Sell
$105
Jul-16-20 Reiterated
H.C. Wainwright
Buy
$101 → $132
Jul-08-20 Downgrade
Ladenburg Thalmann
Buy → Neutral
$50 → $105
Jun-29-20 Reiterated
H.C. Wainwright
Buy
$50 → $101
Jun-29-20 Reiterated
B. Riley FBR
Buy
$74 → $106
Jun-05-20 Upgrade
JP Morgan
Underweight → Neutral
$46
May-28-20 Reiterated
B. Riley FBR
Buy
$53 → $61
May-12-20 Reiterated
H.C. Wainwright
Buy
$33 → $50
Apr-30-20 Reiterated
H.C. Wainwright
Buy
$24 → $33
Nov-27-19 Resumed
B. Riley FBR
Buy
$12
Aug-14-19 Reiterated
H.C. Wainwright
Buy
$10 → $17
Feb-28-19 Downgrade
Piper Jaffray
Overweight → Underweight
$4.50 → $0.25
Dec-18-18 Initiated
Ladenburg Thalmann
Buy
$3
Dec-11-18 Initiated
Oppenheimer
Outperform
$4
Nov-26-18 Upgrade
Piper Jaffray
Neutral → Overweight
Sep-21-18 Upgrade
JP Morgan
Underweight → Overweight
Mar-29-18 Upgrade
Seaport Global Securities
Neutral → Buy
$5
Jan-20-21 02:08PM
Jan-19-21 11:05PM
08:37AM
Jan-15-21 05:50PM
12:56PM
12:47PM
10:51AM Investor's Business Daily
08:18AM
08:00AM
Jan-14-21 04:55PM Investor's Business Daily
12:27PM
Jan-13-21 09:42AM
08:36AM
06:05AM
Jan-12-21 09:09AM
08:54AM
Jan-11-21 07:37PM
12:29PM
07:00AM
Jan-10-21 07:06AM
06:06AM
Jan-08-21 11:50AM
10:41AM
09:36AM
08:42AM
07:25AM
06:05AM
Jan-07-21 06:14PM
06:30AM
06:10AM
Jan-06-21 04:10PM
11:07AM
09:15AM
09:00AM
Jan-04-21 06:28PM
10:18AM
Jan-03-21 06:11AM
Jan-02-21 06:36AM
Jan-01-21 06:10AM
Dec-31-20 08:09AM
06:31AM
Dec-30-20 11:40AM
06:51AM
06:45AM
01:04AM
Dec-29-20 06:19PM
05:11PM
10:12AM
09:34AM
09:33AM
09:01AM
08:38AM
Dec-28-20 06:13PM
02:21PM
11:27AM
09:31AM
09:21AM
09:19AM
09:15AM
06:06AM
Dec-27-20 06:11AM
Dec-26-20 07:30AM
07:05AM
Dec-24-20 12:12PM Investor's Business Daily
06:14AM
06:14AM
Dec-23-20 02:01PM Yahoo Finance Video +10.64%
Dec-22-20 02:41PM Yahoo Finance Video -7.00%
01:35PM
10:35AM
09:53AM
06:48AM
Dec-21-20 05:42PM
11:55AM
09:00AM
05:51AM
Dec-20-20 06:09AM
Dec-19-20 06:33AM
06:09AM
Dec-18-20 04:47PM
11:30AM
07:22AM
Dec-17-20 12:25PM
07:00AM
07:00AM
06:09AM
Dec-16-20 07:25PM
07:08PM
05:00PM
09:59AM
06:14AM
05:51AM
Dec-15-20 06:35AM
06:30AM
06:11AM
Dec-14-20 12:11PM
09:11AM
09:02AM
06:04AM
Dec-13-20 11:11PM
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. It has a partnership agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Trizzino John EVP, CMO and CBO Jan 07 Sale 124.17 506 62,830 287 Jan 07 07:08 PM Trizzino John EVP, CMO and CBO Jan 05 Option Exercise 18.63 13,756 256,243 17,694 Jan 07 07:08 PM Trizzino John EVP, CMO and CBO Jan 05 Sale 112.00 17,407 1,949,522 287 Jan 07 07:08 PM YOUNG JAMES F Director Dec 31 Option Exercise 51.27 11,000 564,000 11,000 Jan 05 05:38 PM DOUGLAS RICHARD Director Dec 31 Option Exercise 50.00 1,000 50,000 28,500 Jan 05 05:42 PM YOUNG JAMES F Director Dec 31 Sale 113.09 11,000 1,244,015 0 Jan 05 05:38 PM Erck Stanley C President and CEO Nov 16 Option Exercise 37.14 52,317 1,942,801 72,811 Nov 18 06:09 PM Erck Stanley C President and CEO Nov 16 Sale 90.65 52,316 4,742,667 20,495 Nov 18 06:09 PM Erck Stanley C President and CEO Oct 01 Sale 108.57 2 217 20,494 Oct 01 05:39 PM Trizzino John EVP, CBO and CFO Sep 30 Sale 110.22 2,250 248,002 5,087 Oct 01 05:40 PM Erck Stanley C President and CEO Sep 30 Sale 110.23 12,231 1,348,200 20,496 Oct 01 05:39 PM Herrmann John A III EVP, Chief Legal Officer Sep 29 Sale 107.31 18,029 1,934,667 275 Sep 30 09:30 PM Glenn Gregory M President, R&D Sep 29 Sale 107.02 19,949 2,134,844 1,561 Sep 30 09:29 PM Trizzino John EVP, CBO and CFO Sep 29 Sale 107.29 18,321 1,965,630 7,337 Sep 30 09:28 PM Erck Stanley C President and CEO Sep 29 Sale 107.80 4,112 443,267 32,727 Sep 30 09:27 PM Erck Stanley C President and CEO Sep 28 Option Exercise 5.95 50,000 297,500 74,606 Sep 30 09:27 PM Trizzino John EVP, CBO and CFO Sep 28 Option Exercise 5.95 29,600 176,120 53,008 Sep 30 09:28 PM Glenn Gregory M President, R&D Sep 28 Option Exercise 5.95 25,000 148,750 46,510 Sep 30 09:29 PM Herrmann John A III EVP, Chief Legal Officer Sep 28 Option Exercise 5.95 24,750 147,263 43,054 Sep 30 09:30 PM Glenn Gregory M President, R&D Sep 28 Sale 110.30 25,000 2,757,456 21,510 Sep 30 09:29 PM Trizzino John EVP, CBO and CFO Sep 28 Sale 110.30 25,000 2,757,456 25,658 Sep 30 09:28 PM Erck Stanley C President and CEO Sep 28 Sale 110.30 25,000 2,757,456 36,839 Sep 30 09:27 PM Herrmann John A III EVP, Chief Legal Officer Sep 28 Sale 110.30 24,750 2,729,879 18,304 Sep 30 09:30 PM EVANS GARY C Director Aug 18 Option Exercise 31.02 10,500 325,700 332,479 Aug 20 06:09 PM Glenn Gregory M President, R&D Aug 18 Option Exercise 33.56 55,921 1,876,525 57,760 Aug 20 06:14 PM Herrmann John A III EVP, Chief Legal Officer Aug 18 Option Exercise 53.82 46,242 2,488,613 46,517 Aug 20 06:20 PM MCMANUS MICHAEL A JR Director Aug 18 Option Exercise 27.60 8,000 220,800 17,951 Aug 20 06:22 PM Trizzino John EVP, CBO and CFO Aug 18 Option Exercise 50.95 42,788 2,179,986 47,875 Aug 20 06:25 PM Trizzino John EVP, CBO and CFO Aug 18 Sale 148.78 42,788 6,366,182 5,087 Aug 20 06:25 PM MCMANUS MICHAEL A JR Director Aug 18 Sale 146.00 8,000 1,168,000 9,951 Aug 20 06:22 PM Herrmann John A III EVP, Chief Legal Officer Aug 18 Sale 144.33 46,242 6,673,982 275 Aug 20 06:20 PM Glenn Gregory M President, R&D Aug 18 Sale 145.20 55,921 8,119,860 1,839 Aug 20 06:14 PM EVANS GARY C Director Aug 18 Sale 150.44 10,500 1,579,620 321,979 Aug 20 06:09 PM Glenn Gregory M President, R&D Jun 18 Option Exercise 42.20 16,749 706,808 18,588 Jun 22 05:29 PM Glenn Gregory M President, R&D Jun 18 Sale 59.53 16,749 997,103 1,839 Jun 22 05:29 PM YOUNG JAMES F Director Jun 03 Buy 48.83 1,500 73,245 1,500 Jun 05 05:04 PM Herrmann John A III SVP, General Counsel May 18 Option Exercise 26.19 12,961 339,448 7,774 May 20 04:35 PM Herrmann John A III SVP, General Counsel May 18 Sale 49.44 12,961 640,792 275 May 20 04:35 PM Glenn Gregory M President, R&D Jan 31 Buy 3.86 1,250 4,825 1,373 Feb 04 05:11 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite